SAN DIEGO, Sept. 23, 2016 /PRNewswire/ -- Biocept, Inc.
(NASDAQ: BIOC), a molecular diagnostics company commercializing and
developing blood-based liquid biopsies to provide information to
physicians to improve the diagnosis and treatment of cancer,
announces that Lyle Arnold, Ph.D.,
Chief Scientific Officer of Biocept, will present at two SelectBio
conferences being held between September
26-30 in San Diego.
Dr. Arnold's presentations will focus on Biocept's patented
Target-Selector™ technology, which uses liquid biopsy to detect and
monitor tumor biomarkers to aid physicians in making treatment
decisions for patients with cancer.
Dr. Arnold will present "Interrogation of Single Circulating
Tumor Cells using Microchannel Enrichment" at the NGS, SCA, SMA
& Mass Spec: Research to Diagnostics 2016 Conference on
September 27, and "Combining CTC
and ctDNA Platforms from the Same Clinical Samples to Expand Liquid
Biopsy Biomarker Content" at the Liquid Biopsies and
Minimally-Invasive Diagnostics 2016 Conference on September
29.
About Biocept
Biocept, Inc. is a molecular diagnostics company with
commercialized assays for lung, breast, gastric, colorectal and
prostate cancers, and melanoma. The Company uses its
proprietary liquid biopsy technology to provide physicians with
information for treating and monitoring patients diagnosed with
cancer. The Company's patented Target Selector™ liquid biopsy
technology platform captures and analyzes tumor-associated
molecular markers in both CTCs and in plasma (ctDNA). With
thousands of tests performed, the platform has demonstrated the
ability to identify cancer mutations and alterations to inform
physicians about a patient's disease and therapeutic
options. For additional information, please visit
www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this release are not strictly historical, including
without limitation statements as to our ability to improve the
diagnosis and treatment of cancer, such statements are
forward-looking, and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
The reader is cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to
numerous risk factors as set forth in our Securities and Exchange
Commission (SEC) filings. The effects of such risks and
uncertainties could cause actual results to differ materially from
the forward-looking statements contained in this release. We do not
plan to update any such forward-looking statements and expressly
disclaim any duty to update the information contained in this press
release except as required by law. Readers are advised to review
our filings with the SEC, which can be accessed over the Internet
at the SEC's website located at www.sec.gov.
Logo -
http://photos.prnewswire.com/prnh/20151013/276540LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/biocepts-proprietary-liquid-biopsy-platform-to-be-featured-at-two-upcoming-molecular-diagnostics-conferences-300333265.html
SOURCE Biocept, Inc.